Company Description
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company.
The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers.
It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to treat patients in VBP101, which is in phase 1 / 2; and VCAR33, a CAR-T therapy designed to target CD33, which is under preclinical studies to treat AML post-transplant.
The company also develops trem-cel + VCAR33 treatment system, CD33-directed CAR-T program, which is under pre-clinical studies for the treatment of AML; VADC45 for the treatment of hematologic malignancies, conditioning, and immune reset, which is under preclinical studies; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-edited HSC therapy and a CD33-CLL1 multi-specific CAR-T therapy, which is under preclinical studies for the treatment of AML.
It has a license agreement with Columbia University and the National Institutes of Health for patents; and with Editas Medicine, Inc. for ex-vivo Cas9 gene-edited HSC therapies for the treatment and/or prevention of hematological malignancies.
The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
| Country | United States |
| Founded | 2015 |
| IPO Date | Feb 5, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 159 |
| CEO | Robert Ang |
Contact Details
Address: 100 Cambridgepark Drive, Suite 101 Cambridge, Massachusetts 02140 United States | |
| Phone | 617 655 6580 |
| Website | vorbio.com |
Stock Details
| Ticker Symbol | VOR |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $18.00 |
| CIK Code | 0001817229 |
| CUSIP Number | 929033108 |
| ISIN Number | US9290331084 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Robert Ang M.B.A., M.D., MBBS | President, Chief Executive Officer and Director |
| Dr. Tirtha Chakraborty Ph.D. | Chief Scientific Officer and Head of Technical Operations |
| Dr. Eyal C. Attar M.D. | Chief Medical Officer |
| Dr. Siddhartha Mukherjee DPHIL, M.D., Ph.D. | Scientific Founder and Chairman of Scientific Advisory Board |
| Dr. Han Choi M.D. | Chief Financial Officer |
| Amy Quinlan | Interim Principal Accounting Officer |
| Tania Philipp | Chief People Officer |
| Samir Vattompadam M.S. | Senior Vice President of Portfolio Strategy and Program Management |
| David Phillips M.B.A. | Senior Vice President and Head of Quality |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 8, 2025 | ARS | Filing |
| Apr 8, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 8, 2025 | DEF 14A | Other definitive proxy statements |
| Apr 3, 2025 | 8-K | Current Report |
| Mar 31, 2025 | EFFECT | Notice of Effectiveness |
| Mar 28, 2025 | PRE 14A | Other preliminary proxy statements |
| Mar 20, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 20, 2025 | S-3 | Registration statement under Securities Act of 1933 |
| Mar 20, 2025 | 10-K | Annual Report |
| Feb 13, 2025 | 144 | Filing |